Biogen Inc. (BIIB) Fair Value 2026

BIIB · Drug Manufacturers - General ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.9 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (21/100)

Quick Summary — As of 2026-08-27, Biogen Inc. (BIIB) trades at $221.50, versus a $287.59 median fair value across its 11 active models — 29.8% above the current price. QOC: 7.9/10. Value Trap Risk: 21/100 (SAFE). 11/13 models active. Within that set, the Bayesian DCF component alone returns $128.33.

Key Facts

Ticker
BIIB
Price
$221.50
Quality Score
7.9/10
Value Trap Risk
21/100
Models Active
11/13
Last Updated
Strength: First Chicago suggests +136.7% upside with 63% confidence
Risk: Limited model coverage (11/13) may reduce confidence

Is Biogen Inc. (BIIB) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Biogen Inc. (BIIB) appears undervalued as of : the median of 11 independent fair value estimates is $287.59, 29.8% above the current price of $221.50. Estimates range from $128.33 to $524.19. BIIB scores 7.9/10 on fundamental quality and 21/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. BIIB’s +29.8% gap is wider than that market norm, and the Drug Manufacturers - General sector median is +29.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Biogen Inc. Stock in 2026? →

What Fair Value Does Each Model Give BIIB?

11 Intrinsic Value Models vs. Current Price ($221.50)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $128.33 -42.1%
Intrinsic · High Conviction
 $214.15 -3.3%
Ensemble · Medium Conviction
 $298.44 +34.7%
Scenario · High Conviction
 $524.19 +136.7%
Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is BIIB's Fair Value Range?

Spread across 11 independent models · $128.33 to $524.19

CirclFi's 11 active models place Biogen Inc. (BIIB) between $128.33 and $524.19 per share, a spread of 138% of the median. The median of that range — $287.59 — is the fair value CirclFi publishes for BIIB, against a current price of $221.50.

Low · Bayesian DCFHigh · First Chicago
$128.33median $287.59$524.19
Where the range comes from
Most bearish modelBayesian DCF$128.33
Most bullish modelFirst Chicago$524.19
Model agreement7 bullish · 3 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for BIIB. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on BIIB, not a CirclFi price target. How each model works →

What Is Biogen Inc. (BIIB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Biogen Inc.'s intrinsic value is estimated at $287.59, suggesting a +29.8% median upside from the current price of $221.50. While 7 models see room for appreciation, model agreement is not unanimous as 3 models flag potential overvaluation. Model dispersion is worth noting: First Chicago targets $524.19 (+136.7%), versus Bayesian DCF at $128.33 (-42.1%). This +178.7% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About BIIB?

11 of 13 models are currently active for BIIB. Of these, 7 models suggest upside while 4 models suggest overvaluation. Taken together, their median fair value for BIIB is $287.59 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $128.33 on its own, implying -42.1% downside from the current price. See which stocks rank higher →

How Does BIIB Rank in Drug Manufacturers - General?

Among 21 Drug Manufacturers - General stocks, BIIB ranks #10 by Quality of Company score. CirclFi's QOC score of 7.9/10 evaluates 32 fundamental signals. A score of 7.9 indicates above-average quality.

Biogen Inc.'s positioning within the Drug Manufacturers - General segment means that biosimilar competition timeline plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.

Is BIIB a Value Trap?

CirclFi's Value Trap algorithm assigns BIIB a score of 21/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Biogen Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Biogen Inc. earns a quality score of 7.9/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +178.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BIIB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BIIB's 11 active models, average confidence is 53%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Biogen Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - General Stocks Should You Also Analyze?

11 related Drug Manufacturers - General stocks with 13-model coverage

AMGNAmgen Inc.QOC 8.4ABBVAbbVie Inc.QOC 7.6BMYBristol-Myers Squibb CompanyQOC 8.5SNYSanofiQOC 7.5GSKGSK plcQOC 8.5PFEPfizer Inc.QOC 7.5GRFSGrifols, S.A.QOC 6.9NVSNovartis AGQOC 2.8NVONovo Nordisk A/SQOC 9.3GILDGilead Sciences, Inc.QOC 9.7MRKMerck & Co., Inc.QOC 9.6

Read investment analysis: AMGN · ABBV · BMY · SNY · GSK · PFE · GRFS · NVS · NVO · GILD · MRK

Which Other Stocks Have a Similar Quality Score to BIIB?

7 companies across all industries closest to BIIB’s Quality of Company score of 7.9/10.

AUDCAudioCodes Ltd.QOC 7.9LBRTLiberty Energy Inc.QOC 7.9JBSSJohn B. Sanfilippo & Son, Inc.QOC 7.9ATOAtmos Energy CorporationQOC 7.9CBRLCracker Barrel Old Country Store, Inc.QOC 7.9DXDynex Capital, Inc.QOC 7.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AUDC · LBRT · JBSS · ATO · CBRL · DX · NVDA

What Else Do Investors Ask About Biogen Inc.’s Valuation?

What is Biogen Inc.'s intrinsic value in 2026?

CirclFi puts Biogen Inc. (BIIB)'s intrinsic value at $287.59 — the median of 11 independent model estimates as of 2026-08-27, ranging from $128.33 to $524.19. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $128.33 on its own. The Quality of Company score is 7.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BIIB overvalued or undervalued right now?

At $221.50, 7 of 11 active models suggest BIIB may be undervalued, while 4 indicate potential overvaluation. The median of all 11 fair value estimates is $287.59, 29.8% above the current price of $221.50 — a consensus view that BIIB is undervalued. The assessment depends on which methodology best fits Biogen Inc.'s business model in Drug Manufacturers - General.

What does a Quality of Company score of 7.9 mean for BIIB?

Biogen Inc.'s QOC of 7.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on BIIB?

CirclFi analyzes BIIB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on BIIB?

Of the 11 models currently active on BIIB, First Chicago is the most bullish at $524.19 per share, and Bayesian DCF is the most bearish at $128.33. CirclFi's published fair value for BIIB is the median of that range, $287.59, not either extreme. The gap between the two ends equals 138% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is BIIB a value trap in 2026?

Biogen Inc.'s Value Trap score is 21/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Biogen Inc. (BIIB) has a median fair value of $287.59 — 29.8% above the current price of $221.50 — as of 2026-08-27.” Source: circlfi.com/stock/BIIB/ · Methodology
Primary sources for this BIIB valuation
  • Financial statements: Biogen Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000875045) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BIIB as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on BIIB.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for BIIB Unlock All 11 — $39/mo